help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 8, 967-974, August 2007; doi:10.1634/theoncologist.12-8-967
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Evolving Strategies for Combined-Modality Therapy for Locally Advanced Head...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Posner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Posner, M.

Head and Neck Cancers

Evolving Strategies for Combined-Modality Therapy for Locally Advanced Head and Neck Cancer

Marshall Posner

Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

Key Words. Head and neck cancer • Induction therapy • Sequential therapy • Combined modality • Treatment • SCCHN

Correspondence: Marshall Posner, M.D., Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA. Telephone: 617-632-3090; Fax: 617-632-4448; e-mail: marshall_posner{at}dfci.harvard.edu

Despite continual advances in the treatment of head and neck cancer, disease-free survival, functional outcome, toxicity of therapy, and overall survival remain less than optimal. While traditional treatment has focused on surgical resection with or without radiation and chemoradiotherapy, newer combined-modality regimens may offer patients a better prognosis, organ preservation, and less morbidity. In this paper, single agents and doublet therapy are reviewed, as are emerging data on the utility of induction therapy, chemoradiotherapy, and surgery as a sequential treatment regimen.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
 JAMAHome page
N. E. Goldstein, E. Genden, and R. S. Morrison
Palliative Care for Patients With Head and Neck Cancer: "I Would Like a Quick Return to a Normal Lifestyle"
JAMA, April 16, 2008; 299(15): 1818 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Eisbruch
Commentary: Induction Chemotherapy for Head and Neck Cancer: Hypothesis-Based Rather Than Evidence-Based Medicine
Oncologist, August 1, 2007; 12(8): 975 - 977.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2007 by AlphaMed Press.